6 results about "Bone cancer" patented technology

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

This patent application belongs to the field of antibody technology, specifically relating to an anti-NGF monoclonal antibody and its applications. The anti-NGF monoclonal antibody of this patent application can specifically bind to TrkA and p75. The anti-NGF monoclonal antibody of this patent application can be used to treat or prevent NGF-mediated diseases, such as autoimmune arthritis, bone cancer pain, osteoarthritis, and fracture pain.

The invention belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound to preparation of a medicine for treating cancer, the structural formula of the benzothiazepine compound is shown in the formula I, and the cancer is selected from at least one of liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment, the compound shown in the formula I shows clear and different activities of resisting human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventor of the invention finds that the benzothiazepine compound as shown in the formula I has excellent activity on various different types of human tumors for the first time by performing activity screening on a small molecular skeleton, and provides an optional scheme for broad-spectrum anti-cancer drugs.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and / or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and / or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.